Literature DB >> 18422690

Cutaneous histopathological findings of Aicardi-Goutières syndrome, overlap with chilblain lupus.

Athanassios Kolivras1, Alec Aeby, Yanick J Crow, Gillian I Rice, Ursula Sass, Josette André.   

Abstract

We report a 2-year-old girl with developmental delay who, from the age of 1 year, developed perniotic lesions of the hands and feet initially diagnosed as chilblain lupus. Histological examination showed features of epidermal necrosis with intraepidermal bulla formation, interface dermatitis, lymphocytic vasculitis with fibrinoid necrosis and thrombi formation, both superficial and deep dermal lymphocytic infiltrate, lymphocytic eccrine hidradenitis and absence of marked dermal edema. Subsequent investigations suggested a clinical diagnosis of Aicardi-Goutières syndrome (AGS), a rare genetic leukoencephalopathy. Recently, both AGS and familial chilblain lupus, an autosomal dominant form of systemic lupus erythematosus (SLE), have been shown to be allelic thus suggesting a common pathogenic basis. In addition, a phenotypic overlap is apparent between SLE and AGS. To our knowledge, this is the first comprehensive dermatopathological report of the cutaneous lesions seen in AGS, and our paper highlights the importance of considering AGS in the differential diagnosis of perniosis and chilblain lupus.

Entities:  

Mesh:

Year:  2008        PMID: 18422690     DOI: 10.1111/j.1600-0560.2007.00900.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  12 in total

1.  The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity.

Authors:  Clinton D Orebaugh; Jason M Fye; Scott Harvey; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Aicardi goutières syndrome is associated with pulmonary hypertension.

Authors:  Laura A Adang; David B Frank; Ahmed Gilani; Asako Takanohashi; Nicole Ulrick; Abigail Collins; Zachary Cross; Csaba Galambos; Guy Helman; Usama Kanaan; Stephanie Keller; Dawn Simon; Omar Sherbini; Brian D Hanna; Adeline L Vanderver
Journal:  Mol Genet Metab       Date:  2018-09-07       Impact factor: 4.797

3.  The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease.

Authors:  Duane A Lehtinen; Scott Harvey; Matthew J Mulcahy; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

Review 4.  Cutaneous Manifestations in Patients With COVID-19: Clinical Characteristics and Possible Pathophysiologic Mechanisms.

Authors:  F González González; C Cortés Correa; E Peñaranda Contreras
Journal:  Actas Dermosifiliogr       Date:  2021-01-28

Review 5.  Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach.

Authors:  Peter A Nigrovic; Pui Y Lee; Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2020-11       Impact factor: 10.793

6.  The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.

Authors:  Kader Cetin Gedik; Lovro Lamot; Micol Romano; Erkan Demirkaya; David Piskin; Sofia Torreggiani; Laura A Adang; Thais Armangue; Kathe Barchus; Devon R Cordova; Yanick J Crow; Russell C Dale; Karen L Durrant; Despina Eleftheriou; Elisa M Fazzi; Marco Gattorno; Francesco Gavazzi; Eric P Hanson; Min Ae Lee-Kirsch; Gina A Montealegre Sanchez; Bénédicte Neven; Simona Orcesi; Seza Ozen; M Cecilia Poli; Elliot Schumacher; Davide Tonduti; Katsiaryna Uss; Daniel Aletaha; Brian M Feldman; Adeline Vanderver; Paul A Brogan; Raphaela Goldbach-Mansky
Journal:  Ann Rheum Dis       Date:  2022-01-27       Impact factor: 27.973

7.  Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies.

Authors:  Laura A Adang; Omar Sherbini; Laura Ball; Miriam Bloom; Anil Darbari; Hernan Amartino; Donna DiVito; Florian Eichler; Maria Escolar; Sarah H Evans; Ali Fatemi; Jamie Fraser; Leslie Hollowell; Nicole Jaffe; Christopher Joseph; Mary Karpinski; Stephanie Keller; Ryan Maddock; Edna Mancilla; Bruce McClary; Jana Mertz; Kiley Morgart; Thomas Langan; Richard Leventer; Sumit Parikh; Amy Pizzino; Erin Prange; Deborah L Renaud; William Rizzo; Jay Shapiro; Dean Suhr; Teryn Suhr; Davide Tonduti; Jacque Waggoner; Amy Waldman; Nicole I Wolf; Ayelet Zerem; Joshua L Bonkowsky; Genevieve Bernard; Keith van Haren; Adeline Vanderver
Journal:  Mol Genet Metab       Date:  2017-08-20       Impact factor: 4.797

8.  Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.

Authors:  David Kavanagh; Sarah McGlasson; Alexa Jury; Jac Williams; Neil Scolding; Chris Bellamy; Claudia Gunther; Diane Ritchie; Daniel P Gale; Yashpal S Kanwar; Rachel Challis; Holly Buist; James Overell; Belinda Weller; Oliver Flossmann; Mark Blunden; Eric P Meyer; Thomas Krucker; Stephen J W Evans; Iain L Campbell; Andrew P Jackson; Siddharthan Chandran; David P J Hunt
Journal:  Blood       Date:  2016-09-23       Impact factor: 25.476

9.  Chilblains in children in the setting of COVID-19 pandemic.

Authors:  David Andina; Lucero Noguera-Morel; Marta Bascuas-Arribas; Jara Gaitero-Tristán; José Antonio Alonso-Cadenas; Silvia Escalada-Pellitero; Ángela Hernández-Martín; Mercedes de la Torre-Espi; Isabel Colmenero; Antonio Torrelo
Journal:  Pediatr Dermatol       Date:  2020-05-22       Impact factor: 1.997

10.  Unusual cutaneous features associated with a heterozygous gain-of-function mutation in IFIH1: overlap between Aicardi-Goutières and Singleton-Merten syndromes.

Authors:  A-C Bursztejn; T A Briggs; Y del Toro Duany; B H Anderson; J O'Sullivan; S G Williams; C Bodemer; S Fraitag; F Gebhard; B Leheup; I Lemelle; A Oojageer; E Raffo; E Schmitt; G I Rice; S Hur; Y J Crow
Journal:  Br J Dermatol       Date:  2015-10-29       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.